Literature DB >> 16137687

SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector ACK1.

Lee Yeow-Fong1, Louis Lim, Ed Manser.   

Abstract

Sorting nexin 9 (SNX9, also referred to as SH3PX1) is a binding partner for the non-receptor and Cdc42-associated kinase (ACK) in Drosophila and mammals. ACK1 is known to bind clathrin and influence EGF receptor endocytosis. SNX9 comprises an N-terminal Src homology domain 3 (SH3), a central PHOX homology (PX) domain, and a carboxyl-terminal coiled-coil region. In order to investigate SNX9 further we have made use of a novel in vivo biotinylation system to label various GST-SH3 domains and perform blot overlays, thereby identifying synaptojanin-1 as a partner for SNX9. Biotinylated SH3 domains were also used for specific identification of target proline-rich sequences in synaptojanin and ACK1 on synthetic peptides arrays. Direct assessment of SH3 binding efficiencies at different positions within the extensive proline-rich regions of these proteins were thus determined. While SNX9 targets a number of sequences within the proline-rich regions of synaptojanin, a single site was identified in human ACK1. By testing the association of various truncations of ACK1 with SNX9 we confirmed the dominant SNX9 binding domain in human ACK1 (residues 920-955). In the presence of SNX9 we find that synaptojanin is able to colocalize with distinct ACK1 containing vesicles, indicating that this tyrosine kinase is linked to many components involved in vesicle dynamics including clathrin, AP2 and synaptojanin-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137687     DOI: 10.1016/j.febslet.2005.07.093

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

1.  A robust protocol to map binding sites of the 14-3-3 interactome: Cdc25C requires phosphorylation of both S216 and S263 to bind 14-3-3.

Authors:  Perry M Chan; Yuen-Wai Ng; Ed Manser
Journal:  Mol Cell Proteomics       Date:  2010-12-28       Impact factor: 5.911

Review 2.  Ever-expanding network of dynamin-interacting proteins.

Authors:  Yoonju Kim; Sunghoe Chang
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

3.  Regulation of IRSp53-dependent filopodial dynamics by antagonism between 14-3-3 binding and SH3-mediated localization.

Authors:  Jeffrey M Robens; Lee Yeow-Fong; Elsa Ng; Christine Hall; Ed Manser
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

Review 4.  Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2010-08       Impact factor: 6.384

5.  The Sac domain-containing phosphoinositide phosphatases: structure, function, and disease.

Authors:  FoSheng Hsu; Yuxin Mao
Journal:  Front Biol (Beijing)       Date:  2013-08

Review 6.  Endocytosis, Metastasis and Beyond: Multiple Facets of SNX9.

Authors:  Nawal Bendris; Sandra L Schmid
Journal:  Trends Cell Biol       Date:  2016-12-16       Impact factor: 20.808

7.  Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli.

Authors:  Maria L Galisteo; Yan Yang; Jesus Ureña; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-15       Impact factor: 11.205

8.  Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2.

Authors:  Wing Chan; Rui Tian; Yeow-Fong Lee; Soon Tuck Sit; Louis Lim; Ed Manser
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

9.  Characterization of PXK as a protein involved in epidermal growth factor receptor trafficking.

Authors:  Hiroshi Takeuchi; Takako Takeuchi; Jing Gao; Lewis C Cantley; Masato Hirata
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

10.  Regulation of Ack1 localization and activity by the amino-terminal SAM domain.

Authors:  Victoria Prieto-Echagüe; Azad Gucwa; Deborah A Brown; W Todd Miller
Journal:  BMC Biochem       Date:  2010-10-27       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.